Does metformin administration improve fracture healing? A systematic review of preclinical studies
Abstract
Introduction
Fracture healing plays a critical role in the recovery from bone injuries and functional mobility. However, conditions such as diabetes mellitus increase the vulnerability to disruptions in this process. Diabetes, a systemic inflammatory disorder, is associated with impaired osseus healing and increased fracture vulnerability. Metformin, an oral antidiabetic medication, has shown potential in enhancing fracture healing; however, its clinical effectiveness remains controversial. We aim to elucidate the effects of metformin on fracture healing and explore potential mechanisms of action.
Methods
Systematic literature search was performed in PubMed, ScienceDirect, and Google Scholar until January 17, 2024. Criteria encompassed English-language, peer-reviewed articles using in vivo models. This systematic review was conducted in accordance with PRISMA guideline.
Results
A total of 7 studies were included in this study. Diabetes impedes fracture healing through inflammation- induced osteoblast cell death, and metformin, commonly prescribed for diabetes, exhibits anti-inflammatory properties. Studies indicated metformin's positive effects on bone repair through AMPK activation, increased collagen production, and enhanced angiogenesis. However, some studies reported inferior bone quality and limited impact on normoglycemic conditions.
Conclusion
Metformin emerges as a promising adjunct in fracture healing, particularly in diabetic patients, by promoting osteogenesis and…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.